Georgios Trichas Email & Phone Number

Helsinki, FI

Founded Coryfea Biosciences, a life sciences consultancy company based in Helsinki, Finland to provide business development consulting services to biotech companies globally with a specific focus on oncology/immuno-oncology, and cell and gene therapy.

Parkville, Victoria, AU

• 66ten is WEHI’s first strategic investment fund investing AUS$ 66M over 10 years, the largest internal pre-seed and seed fund in an Australian medical research institute, aiming to bridge the gap between discovery and.
• Reviewer on investment proposals incl. technical assessment, scientific and commercial strategy, product development, preclinical strategy.
• Delivered market and competitive analysis assessment for pre-clinical cell therapy vaccine programme in cancer.

Hammersmith, England, GB

• Provided business development services with end-to-end deal making responsibilities to Achilles Therapeutics to support the company in securing strategic pharma partners to diversify their oncology pipeline by.
• Engaged with 15+ pharma companies, supported the development of pitching materials tailored to their areas of partnering interest, effectively highlighting the value proposition, and supported term sheet preparation by.
• Led Achilles’ in-licencing deal with Weizmann Institute of Science in Israel to exclusively access validated TCR leads, targets and identification platform enabling Achilles to expand into TCR therapeutics in cancer.
• Co-led with Achilles’ CBO a Research Collaboration agreement with Arcturus Therapeutics to explore second-generation personalized mRNA cancer vaccines using Arcturus’ world-leading self-amplifying mRNA platform.

Hammersmith, England, GB

• Held senior operational positions of increasing responsibility to a VP level and contributed to the successful operational evolution of Achilles from a newco to a mature clinical stage company.
• Led the company’s operational strategy for commercial manufacturing scale-up to build a 100k sq ft GMP manufacturing facility in the UK, including the site selection, lease negotiation and concept design.
• Led the company’s manufacturing expansion strategy to the US; Led the CDMO selection process and negotiated the commercial deal with the selected CDMO, Center for Breakthrough Medicines.
• Led the company’s commercial and operational strategy for the supply of the patient-specific neoantigen peptides, that represent each patient’s tumor targets, an essential starting material for Achilles’ personalised.
• Worked closely with Business Development on identifying new opportunities, prepared pitching material for potential partners, participated in partnering meetings, led on due diligence, and reviewed deal terms.
• Supported the company’s £100M Series B financing round in 2019, incl. pitch deck preparation and managing the due diligence process for investors; Member of the IPO team in 2021 to provide information on Manufacturing.

Hammersmith, England, GB

Hammersmith, England, GB

Hammersmith, England, GB

• Represented the Wellcome Trust on the Board of Directors as Investment Director to support the company in its mission to develop safe and efficacious drugs for the treatment of atrial fibrillation, the most common type.

London, UK, GB

• Operated with 10 other Partners a budget of £100M p.a. to make programme-related investments (PRI) to biotech, pharma and academia globally to support the early stages of product development in life sciences.
• Responsible for a portfolio of 14 PRIs of total value over £50M; monitored the programme performance against the project plan, managed FTE resources, tracked and approved milestone achievement, oversaw budget.
• Executed nine PRIs via convertible loan/royalty financing in oncology, neurology and infectious diseases. Evaluated and made investment recommendations for over 600 programmes.
• Led the $340m licensing deal with Merck of the Wellcome-funded HCN2 small-molecule programme from King’s College London for the treatment of neuropathic pain. The deal was quoted by the Financial Times to be the most.
• Led a £4M PRI in Swiss vaccine biotech GlycoVaxyn to support the development of a novel Shigella vaccine; the company was acquired by GSK for £125M. Led a £10M follow-on PRI to GSK for the Phase 2 clinical development.
• Head of the £30M Wellcome/EPSRC Innovative Engineering for Health Initiative to support innovative engineering solutions to intractable problems in medicine or public health.

London, UK, GB

London, UK, GB

London, England, GB

• Part of the deal team in the formation of Achilles Therapeutics; Led freedom to operate and competitive landscape analysis as well as participated in operational activities.
• Participated in the assessment of new investment opportunities in life sciences for new venture formation and company financing.

London, Greater London, GB

• Established R&D collaborations with biopharma industry and negotiated IP and contracts.
• Led the formation of the £4m MRC MATURA consortium with 12 universities and 9 companies to identify biomarkers for patient stratification in rheumatoid arthritis.
• Participated in deal team negotiating commercial terms in a £ multimillion deal with pharma.
• Screened and performed due diligence on translational academic projects including IP protection and competitive analysis.
• Identified funding opportunities and prepared grant proposals to UK/EU funders of total value of £21m, including a drug discovery programme to develop PI3K inhibitors in diabetes.
• Awarded QMUL Staff Bonus for outstanding performance (top 5% of staff).

Oxford, Oxfordshire, GB

• Researched heart development and the initiation of heartbeat in mouse, supported by the British Heart Foundation.
• Developed ex vivo assay for screening novel drug candidates for effect on heart function.
• Initiated and led a drug-discovery research collaboration with Prof Bart Vanhaesebroeck, UCL, on a novel PI3K drug-target validation programme, published in Nature Communications.

Dphil, Human Anatomy And Genetics

Msc, Molecular Basis Of Human Diseases

Bsc, Biology